bioAffinity Technologies, Inc.
BIAFW · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.08 | 0.02 | -0.03 |
| FCF Yield | -78.46% | -38.55% | -40.04% | -14.87% |
| EV / EBITDA | 0.78 | -1.73 | -2.06 | -4.19 |
| Quality | ||||
| ROIC | -23.93% | -100.27% | -94.82% | -71.81% |
| Gross Margin | 27.00% | 19.92% | 26.21% | 22.28% |
| Cash Conversion Ratio | 0.49 | 0.65 | 0.62 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 176.24% | 582.56% | 1,054.62% | 1,149.25% |
| Free Cash Flow Growth | 6.92% | -57.20% | -0.92% | 2.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.42 | 0.03 | -0.36 | -0.14 |
| Interest Coverage | -427.93 | -240.49 | -169.66 | -117.65 |
| Efficiency | ||||
| Inventory Turnover | 29.96 | 23.12 | 35.27 | 62.15 |
| Cash Conversion Cycle | -49.26 | -69.76 | -41.56 | -3.90 |